These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 33243256)

  • 1. High output cardiac failure in 3 patients with hereditary hemorrhagic telangiectasia and hepatic vascular malformations, evaluation of treatment.
    Olsen LB; Kjeldsen AD; Poulsen MK; Kjeldsen J; Fialla AD
    Orphanet J Rare Dis; 2020 Nov; 15(1):334. PubMed ID: 33243256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output.
    Dupuis-Girod S; Ginon I; Saurin JC; Marion D; Guillot E; Decullier E; Roux A; Carette MF; Gilbert-Dussardier B; Hatron PY; Lacombe P; Lorcerie B; Rivière S; Corre R; Giraud S; Bailly S; Paintaud G; Ternant D; Valette PJ; Plauchu H; Faure F
    JAMA; 2012 Mar; 307(9):948-55. PubMed ID: 22396517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers.
    Al-Samkari H; Albitar HA; Olitsky SE; Clancy MS; Iyer VN
    Orphanet J Rare Dis; 2019 Nov; 14(1):256. PubMed ID: 31727111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia.
    Mitchell A; Adams LA; MacQuillan G; Tibballs J; vanden Driesen R; Delriviere L
    Liver Transpl; 2008 Feb; 14(2):210-3. PubMed ID: 18236396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Bevacizumab: a new success in hereditary hemorrhagic telangiectasia].
    Bennesser Alaoui H; Lehraiki M; Hamaz S; El Attar N; Fakhreddine N; Serraj K
    Rev Med Interne; 2015 Sep; 36(9):623-5. PubMed ID: 25595875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcome of patients with hereditary hemorrhagic telangiectasia and severe hepatic involvement after orthotopic liver transplantation: a single-center study.
    Dupuis-Girod S; Chesnais AL; Ginon I; Dumortier J; Saurin JC; Finet G; Decullier E; Marion D; Plauchu H; Boillot O
    Liver Transpl; 2010 Mar; 16(3):340-7. PubMed ID: 20209594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab to Treat Cholangiopathy in Hereditary Hemorrhagic Telangiectasia: Be Cautious: A Case Report.
    Maestraggi Q; Bouattour M; Toquet S; Jaussaud R; Kianmanesh R; Durand F; Servettaz A
    Medicine (Baltimore); 2015 Nov; 94(46):e1966. PubMed ID: 26579805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hereditary haemorrhagic telangiectasia: to transplant or not to transplant - is there a right time for liver transplantation?
    Muller YD; Oppliger R; Breguet R; Meyer P; Rubbia-Brandt L; Petignat PA; Harr T; Dayer E; Seebach JD
    Liver Int; 2016 Dec; 36(12):1735-1740. PubMed ID: 27864873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful therapy with bevacizumab in a case of hereditary hemorrhagic telangiectasia.
    Kochanowski J; Sobieszczańska M; Tubek S; Żurek M; Pawełczak J
    Hum Vaccin Immunother; 2015; 11(3):680-1. PubMed ID: 25839219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blessing for the bleeder: bevacizumab in hereditary hemorrhagic telangiectasia.
    Epperla N; Hocking W
    Clin Med Res; 2015 Mar; 13(1):32-5. PubMed ID: 24667223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic therapy with bevacizumab in patients with hereditary hemorrhagic telangiectasia (HHT).
    Chavan A; Schumann-Binarsch S; Luthe L; Nickau B; Elsässer A; Kühnel T; Geisthoff U; Köhne H
    Vasa; 2013 Mar; 42(2):106-10. PubMed ID: 23485837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulmonary vascular complications of hereditary haemorrhagic telangiectasia.
    Circo S; Gossage JR
    Curr Opin Pulm Med; 2014 Sep; 20(5):421-8. PubMed ID: 25032812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasia.
    Azzopardi N; Dupuis-Girod S; Ternant D; Fargeton AE; Ginon I; Faure F; Decullier E; Roux A; Carette MF; Gilbert-Dussardier B; Hatron PY; Lacombe P; Leguy-Seguin V; Rivière S; Corre R; Bailly S; Paintaud G
    MAbs; 2015; 7(3):630-7. PubMed ID: 25751241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abdominal manifestations of hereditary hemorrhagic telangiectasia: a series of 333 patients over 15 years.
    Welle CL; Welch BT; Brinjikji W; Ehman EC; Venkatesh SK; Johnson MP; Iyer VN; Leise MD; Wood CP
    Abdom Radiol (NY); 2019 Jul; 44(7):2384-2391. PubMed ID: 30888464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic vascular malformations in hereditary hemorrhagic telangiectasia.
    Khalid SK; Garcia-Tsao G
    Semin Liver Dis; 2008 Aug; 28(3):247-58. PubMed ID: 18814078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia.
    Buscarini E; Botella LM; Geisthoff U; Kjeldsen AD; Mager HJ; Pagella F; Suppressa P; Zarrabeitia R; Dupuis-Girod S; Shovlin CL;
    Orphanet J Rare Dis; 2019 Feb; 14(1):28. PubMed ID: 30717761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical management of haemorrhagic hereditary telangiectasia in adult patients.
    Riera-Mestre A; Ribas J; Castellote J
    Med Clin (Barc); 2019 Apr; 152(7):274-280. PubMed ID: 30502301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hereditary hemorrhagic telangiectasia, liver vascular malformations and cardiac consequences.
    Ginon I; Decullier E; Finet G; Cordier JF; Marion D; Saurin JC; Dupuis-Girod S
    Eur J Intern Med; 2013 Apr; 24(3):e35-9. PubMed ID: 23312966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tranexamic acid-bevacizumab synergy in HHT patients presenting pulmonary arteriovenous malformations.
    Lacout A; Marcy PY; El Hajjam M; Lacombe P
    Med Hypotheses; 2012 Nov; 79(5):605-6. PubMed ID: 22959314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron deficiency anemia related to hereditary hemorrhagic telangiectasia: response to treatment with bevacizumab.
    Fleagle JM; Bobba RK; Kardinal CG; Freter CE
    Am J Med Sci; 2012 Mar; 343(3):249-51. PubMed ID: 22227516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.